Drug

Qilu Pharma’s QLS31905 Wins FDA Orphan Drug Designation – First‑in‑Class Claudin18.2/CD3 Bispecific Enters Phase III for Pancreatic Cancer

Qilu Pharmaceutical Co., Ltd. announced that QLS31905, its Claudin18.2/CD3 bispecific T‑cell engager (BsAb), has received...

Company Drug

Bayer/Regeneron’s Eylea HD Wins Japan Approval for RVO – Third Indication Nod with Extended Dosing Demonstrates 3 Fewer Injections

Fineline Cube Mar 25, 2026

Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Eylea HD (aflibercept) injection 8...

Company Drug

Sanofi’s Dupixent Wins Japan Approval for Bullous Pemphigoid – Seventh Indication Expands IL‑4/IL‑13 Franchise

Fineline Cube Mar 25, 2026

Sanofi S.A. (NASDAQ: SNY) announced that Dupixent (dupilumab) has received marketing approval from Japan’s Ministry...

Company Drug

Haixi Pharma Advances HXP056 to Phase II – Oral Multi‑Selective Therapy for Wet AMD and Hemorrhagic Retinal Diseases

Fineline Cube Mar 25, 2026

Fujian Haixi Pharmaceuticals Co., Ltd. (HKG: 2637) announced the initiation of a Phase II clinical...

Company Drug

IASO Bio Wins Japan PMDA Approval for Fucaso CAR‑T – BCMA Therapy Enters Phase III in Relapsed/Refractory Multiple Myeloma

Fineline Cube Mar 25, 2026

IASO Biotherapeutics announced receiving tacit clinical approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA)...

Company Drug

Hope Medicine Doses First Patient in HMI-115 Phase III – First-in-Class Non-Hormonal Endometriosis Therapy Advances in China

Fineline Cube Mar 25, 2026

Hope Medicine Inc. announced first patient dosing in a Phase III clinical study evaluating HMI-115,...

Company Drug

Kelun‑Biotech’s SKB103 Wins NMPA Approval – Novel TAA‑PD‑L1 Bispecific ADC Enters Clinical Trials for Advanced Solid Tumors

Fineline Cube Mar 25, 2026

Sichuan Kelun‑Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that its SKB103, a novel TAA‑PD‑L1 bispecific...

Company Drug

Alphamab Oncology Doses First Patient in Phase III KN026 Study – Bispecific HER2 Antibody Targets Adjuvant Breast Cancer

Fineline Cube Mar 24, 2026

Alphamab Oncology (HKG: 9966) announced first patient dosing in a Phase III clinical study of...

Company Drug

Shenzhen Salubris Wins NMPA Approval for SAL0150 – Oral Long-Acting Diabetes/Obesity Drug Targets Weekly Dosing Regimen

Fineline Cube Mar 24, 2026

Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced clinical trial approval from China’s National Medical...

Company Drug

GSK’s Risvutatug Rezetecan Wins Japan ODD – B7-H3 ADC Targets Small-Cell Lung Cancer with Phase 1 Durable Responses

Fineline Cube Mar 24, 2026

GlaxoSmithKline (GSK; NYSE: GSK) announced that risvutatug rezetecan (Ris-Rez), a B7-H3-targeted antibody-drug conjugate (ADC), received...

Company Deals Drug

Belief BioMed Partners with Grand Life Sciences on BBM-H803 – AAV Gene Therapy for Hemophilia A Targets Greater China Market

Fineline Cube Mar 24, 2026

Belief BioMed (“BBM”) and Grand Life Sciences Group Co., Ltd. (HKG: 0512) announced an exclusive...

Company Drug

Qilu Pharma’s QLS1317 Wins NMPA Approval – First‑in‑Class MSI‑H Targeted Therapy Enters Solid Tumor Clinical Trials

Fineline Cube Mar 24, 2026

Qilu Pharmaceutical Co., Ltd. announced that its self‑developed Category 1 innovative drug, QLS1317 tablets, has...

Company Drug

Innovent’s IBI302 Hits STAR Trial Primary Endpoint – Dual VEGF/Complement Inhibitor Shows 16‑Week Dosing and 50% Macular Atrophy Reduction in nAMD

Fineline Cube Mar 24, 2026

Innovent Biologics, Inc. (HKG: 1801) announced that its Phase III STAR study (NCT05972473) evaluating efdamrofusp...

Company Drug

RemeGen Secures Fourth NMPA Approval for Disitamab Vedotin – HER2‑Low Breast Cancer with Liver Metastases Indication Expands ADC Franchise

Fineline Cube Mar 24, 2026

RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) announced NMPA approval for a new indication of...

Company Drug

Henlius Biotech’s HLX18 Wins NMPA Approval – Nivolumab Biosimilar Enters Phase I Solid Tumor Trials in China

Fineline Cube Mar 23, 2026

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that HLX18, a recombinant humanized anti‑PD‑1 monoclonal antibody...

Company Drug

Lepu Biopharma Wins NMPA Approval for Perioperative HNSCC Trial – First‑in‑World EGFR ADC + PD‑1 Combination Advances to Clinic

Fineline Cube Mar 23, 2026

Lepu Biopharma Co., Ltd. (HKG: 2157) announced NMPA IND approval for a groundbreaking Phase II/III...

Company Drug

Biokin Pharma’s BL‑ARC002 Wins NMPA Approval – First‑in‑Class Antibody‑Radionuclide Conjugate Enters Solid Tumor Trials

Fineline Cube Mar 23, 2026

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its BL‑ARC002 injection, a Category 1...

Company Drug

Hansoh Pharma Wins NMPA Approval for Two Category 1 Drugs – HS‑20152 and HS‑10587 Enter Clinical Trials in Rare Disease and Oncology

Fineline Cube Mar 23, 2026

Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that two Category 1 innovative drugs have...

Company Deals Drug

Novartis Acquires SNV4818 from Synnovation – USD 3 Billion Deal for Pan‑Mutant PI3Kα Inhibitor in Breast Cancer

Fineline Cube Mar 23, 2026

Novartis AG (NYSE: NVS) announced a definitive agreement to acquire SNV4818, a pan‑mutant‑selective PI3Kα inhibitor,...

Company Drug

Grand Pharma Wins NMPA Approval for GPN01768 – First Targeted Therapy for Demodex Blepharitis in China

Fineline Cube Mar 23, 2026

Grand Pharmaceutical Group (HKG: 0512) announced that its licensed‑in global innovative ophthalmic drug GPN01768 [TP‑03,...

Drug

Qilu Pharma’s QLS31905 Wins FDA Orphan Drug Designation – First‑in‑Class Claudin18.2/CD3 Bispecific Enters Phase III for Pancreatic Cancer

Bayer/Regeneron’s Eylea HD Wins Japan Approval for RVO – Third Indication Nod with Extended Dosing Demonstrates 3 Fewer Injections

Sanofi’s Dupixent Wins Japan Approval for Bullous Pemphigoid – Seventh Indication Expands IL‑4/IL‑13 Franchise

Haixi Pharma Advances HXP056 to Phase II – Oral Multi‑Selective Therapy for Wet AMD and Hemorrhagic Retinal Diseases

IASO Bio Wins Japan PMDA Approval for Fucaso CAR‑T – BCMA Therapy Enters Phase III in Relapsed/Refractory Multiple Myeloma

Hope Medicine Doses First Patient in HMI-115 Phase III – First-in-Class Non-Hormonal Endometriosis Therapy Advances in China

Kelun‑Biotech’s SKB103 Wins NMPA Approval – Novel TAA‑PD‑L1 Bispecific ADC Enters Clinical Trials for Advanced Solid Tumors

Alphamab Oncology Doses First Patient in Phase III KN026 Study – Bispecific HER2 Antibody Targets Adjuvant Breast Cancer

Shenzhen Salubris Wins NMPA Approval for SAL0150 – Oral Long-Acting Diabetes/Obesity Drug Targets Weekly Dosing Regimen

GSK’s Risvutatug Rezetecan Wins Japan ODD – B7-H3 ADC Targets Small-Cell Lung Cancer with Phase 1 Durable Responses

Belief BioMed Partners with Grand Life Sciences on BBM-H803 – AAV Gene Therapy for Hemophilia A Targets Greater China Market

Qilu Pharma’s QLS1317 Wins NMPA Approval – First‑in‑Class MSI‑H Targeted Therapy Enters Solid Tumor Clinical Trials

Innovent’s IBI302 Hits STAR Trial Primary Endpoint – Dual VEGF/Complement Inhibitor Shows 16‑Week Dosing and 50% Macular Atrophy Reduction in nAMD

RemeGen Secures Fourth NMPA Approval for Disitamab Vedotin – HER2‑Low Breast Cancer with Liver Metastases Indication Expands ADC Franchise

Henlius Biotech’s HLX18 Wins NMPA Approval – Nivolumab Biosimilar Enters Phase I Solid Tumor Trials in China

Lepu Biopharma Wins NMPA Approval for Perioperative HNSCC Trial – First‑in‑World EGFR ADC + PD‑1 Combination Advances to Clinic

Biokin Pharma’s BL‑ARC002 Wins NMPA Approval – First‑in‑Class Antibody‑Radionuclide Conjugate Enters Solid Tumor Trials

Hansoh Pharma Wins NMPA Approval for Two Category 1 Drugs – HS‑20152 and HS‑10587 Enter Clinical Trials in Rare Disease and Oncology

Novartis Acquires SNV4818 from Synnovation – USD 3 Billion Deal for Pan‑Mutant PI3Kα Inhibitor in Breast Cancer

Grand Pharma Wins NMPA Approval for GPN01768 – First Targeted Therapy for Demodex Blepharitis in China

You Missed

Qilu Pharma’s QLS31905 Wins FDA Orphan Drug Designation – First‑in‑Class Claudin18.2/CD3 Bispecific Enters Phase III for Pancreatic Cancer

WuXi Biologics Reports 2025 Revenue Growth 16.7% – Net Profit Surges 46.3% on Record 209 New Projects

Bayer/Regeneron’s Eylea HD Wins Japan Approval for RVO – Third Indication Nod with Extended Dosing Demonstrates 3 Fewer Injections

Sciwind Biosciences Files Hong Kong IPO Prospectus – GLP‑1 Obesity Pipeline Targets R&D Funding for Weight Management Franchise